HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	9/18/2000 4:48:45 PM
From: nigel bates	of 1022

Sept. 18 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - news) today announced that it has signed a second antibody humanization agreement with Eli Lilly and Company (Lilly). Under the agreement, PDL will humanize one or more murine antibodies directed to a single target. PDL will receive a non-refundable, non-creditable upfront signing fee of $1.36 million, milestone payments upon the achievement of specified objectives, annual maintenance fees and royalties on sales of the humanized antibody. PDL recognizes upfront fees from humanization contracts over the period in which the work is conducted. ``This is the third humanization agreement which PDL has entered into this year,'' said Robert L. Kirkman, M.D., Vice President, Business Development and Corporate Communications. ``In addition, PDL has already entered into patent or patent rights agreements in 2000 covering up to nine humanized antibodies. We believe this continued flow of new agreements further validates PDL's humanization technology.'' PDL receives royalties from sales of the four humanized antibody products that are currently marketed. Forty additional humanized antibodies are in clinical trials ....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next